^
Association details:
| Biomarker: | LRP1B overexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | pegylated liposomal doxorubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer
Published date:
10/22/2021
Excerpt:
Pegylated liposomal doxorubicin (PLD)…ovarian cancer (OC)...OC cells with increased expression of LRP1B were more sensitive to PLD. LRP1B staining score was associated with clinicopathological features, response to therapy, and survival outcomes. Higher LRP1B levels were associated with prolonged progression-free survival. Our results support a possible role of LRP1B as a predictor of response to PLD in patients with OC.
DOI:
10.1159/000517372
